Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma
Status:
Withdrawn
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This pilot early phase I trial studies how well fluorothymidine F-18 positron emission
tomography (PET) works in imaging patients with intermediate or high grade soft tissue
sarcoma. Fluorothymidine F-18 PET may provide useful information about the tumor's response
to treatment and may give the doctors early results that would better help to plan the
post-surgical therapy.